• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Regulatory/Compliance

Another BD Alaris infusion pump recall is Class I

April 16, 2021 By Sean Whooley

BD logo

The FDA has identified another recall for the Alaris infusion pump from BD (NYSE:BDX) as Class I, the most serious kind of recall. BD’s latest recall, initiated on March 3, 2021, involves its BD Alaris infusion pump module system, which includes an infusion pump and vital signs monitoring system with a PC unit, the Guardrails […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Recalls, Regulatory/Compliance Tagged With: BD, Becton Dickinson, FDA

OncoSec wins CE mark for electroporation device to treat solid tumors

April 14, 2021 By Sean Whooley

Oncosec

OncoSec Medical (NSDQ:ONCS) announced today that it received CE mark approval for its next-generation device to enable better uptake of anti-cancer therapies. GenPulse, part of OncoSec’s electroporation device platform for treating solid tumors, is designed to apply short electric impulses to a tumor, according to a news release. Get the full story at our sister site, […]

Filed Under: Oncology, Regulatory/Compliance Tagged With: OncoSec Medical

Genentech wins FDA approval for Xolair prefilled syringe

April 12, 2021 By Sean Whooley

Genentech logo updated

Genentech announced today that the FDA approved its supplemental biologics license application for the Xolair prefilled syringe. South San Francisco-based Genentech touts the Xolair (omalizumab) prefilled syringe for self-injection across all approved U.S. indications as the only FDA-approved biologic designed to target and block immunoglobulin E (IgE) for treating moderate to severe persistent allergic asthma, […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Pharmaceuticals, Regulatory/Compliance Tagged With: FDA, Genentech

Teva Pharmaceuticals receives European approval for Spiromax inhalers

April 8, 2021 By Sean Whooley

Teva

Teva Pharmaceuticals announced today that it received European marketing authorization for its Seffalair and BroPair Spiromax inhalers. Seffalair Spiromax and its duplicate BroPair Spiromax (salmeterol xinafoate/ fluticasone propionate, 12.75/100 and 12.75/202 micrograms delivered doses) received approval as a maintenance treatment for asthma in adults and adolescents aged 12 years and older, according to a news […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Pharmaceuticals, Regulatory/Compliance, Respiratory Tagged With: Teva, Teva Pharmaceuticals

FDA approves inhaled pulmonary hypertension treatment from United Therapeutics

April 1, 2021 By Sean Whooley

Tyvaso United Therapeutics

United Therapeutics (NSDQ:UTHR) announced today that it received FDA approval for its Tyvaso inhalation solution for pulmonary hypertension. Research Triangle Park, N.C.-based United Therapeutics’ Tyvaso (treprostinil) inhalation solution is designed to treat patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) to improve exercise ability, according to a news release. With approval, Tyvaso now […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Pharmaceuticals, Regulatory/Compliance, Respiratory Tagged With: FDA, United Therapeutics

BlueStar Genomics gains breakthrough nod for pancreatic cancer test

March 31, 2021 By Sean Whooley

Bluestar Genomics

Bluestar Genomics announced today that it received FDA breakthrough device designation for its pancreatic cancer test. San Diego-based Bluestar’s proprietary noninvasive pancreatic cancer detection test is designed for use with patients with new-onset diabetes, according to a news release. The test uses a standard blood draw to assess whether an individual has an abnormal epigenomic […]

Filed Under: Clinical Trials, Diabetes, Diagnostics, Featured, Food & Drug Administration (FDA), Regulatory/Compliance Tagged With: Bluestar Genomics, FDA

BD expands recall of ChloraPrep 3 ml applicator

March 25, 2021 By Sean Whooley

BD-logo-new

BD announced that it revised a previous press release from last week to expand a voluntary recall of its ChloraPrep 3 mL applicator. Franklin Lakes, N.J.-based BD initiated the recall for specified catalog numbers of the applicator device on June 23, 2020, due to possible fungal contamination under certain environmental conditions, according to a news […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Recalls, Regulatory/Compliance Tagged With: BD, Becton Dickinson

J&J Vision wins Japanese approval for first drug-releasing contact lens

March 25, 2021 By Sean Whooley

Johnson & Johnson Vision Acuvue Theravision

Johnson & Johnson Vision announced that it received approval in Japan for its Acuvue Theravision lens with Ketotifen. The company touts the lens as the first and only vision-correcting contact lens that relieves allergic eye itch through drug delivery, according to a news release. Japan’s Ministry of Health, Labour and Welfare (MHLW) approved the lens, […]

Filed Under: Drug-Device Combinations, Featured, Optical/Ophthalmic, Regulatory/Compliance Tagged With: Johnson & Johnson

Eitan Medical wins EU clearance for Sapphire infusion pump

March 10, 2021 By Sean Whooley

Eitan Medical

Eitan Medical announced that it received European Union Medical Device Recognition (MDR) certification for its Sapphire infusion pump. Approval for the Sapphire infusion pump, along with its accessories and administration sets, was granted in January 2021, according to a news release. The certification is EU MDR 2017/45. Sapphire includes upgraded Rev15 software, also EU MDR […]

Filed Under: Drug-Device Combinations, Featured, Regulatory/Compliance Tagged With: Eitan Medical

FDA tentatively approves first generic version of Symbicort inhalation aerosol

March 8, 2021 By Sean Whooley

Viatris Kindeva Drug Delivery

Viatris (NSDQ:VTRS) and Kindeva Drug Delivery announced today that the FDA granted tentative approval of the first generic version of Symbicort. Symbicort, an inhalation aerosol is indicated for certain patients with asthma or chronic obstructive pulmonary disease (COPD). The drug had U.S. branded sales of $3.5 billion for the 12 months ended January 2021, according […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Legal News, Pharmaceuticals, Regulatory/Compliance, Respiratory Tagged With: AstraZeneca plc, FDA, Kindeva Drug Delivery, Viatris

  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Interim pages omitted …
  • Go to page 81
  • Go to Next Page »

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Footer

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS